COVID-19 VACCINE PROCUREMENT MECHANISMS

COVAX & The African Union

Charles Shey Wiysonge

Twitter: @CharlesShey

Email: Charles.Wiysonge@mrc.ac.za



Plan

- 1. Covid-19 cases and deaths in Africa
- 2. The scramble for Covid-19 vaccines worldwide
- 3. The goal of COVAX
- 4. Covid-19 supply agreements: COVAX, the African Union, etc
- 5. Lessons from access to non-Covid vaccines: the Gavi model
- 6. Covid-19 vaccine rollout worldwide
- 7. Covid-19 vaccine rollout through Covax
- 8. Covid-19 vaccine roll out in Africa
- 9. Conclusion: access to HIV drugs in Africa in the 1990s



Covid-19 cases and deaths in Africa

WHO region AFRO 47 countries	Cumul cases		Cases (%)	Cumul deaths		Deaths (%)	CFR (%)
	2,915,874	South Africa (56.6%), Ethiopia (6.2%), Algeria (5%), Kenya (4.8%), Nigeria (4.6%)	72.4	74,486	South Africa (68.8%), Algeria (4.1%), Ethiopia (3.4%), Nigeria (2.7%), Kenya (2.6%)	69.3	2.6
EMRO 7 countries*	1,109,883	Morocco (44%), Tunisia (21.7%), Egypt (17.1%)	27.6	33,033	Egypt (34.1%), Morocco (26.4%), Tunisia (25.3%)	30.7	3
Total	4,025,757	South Africa (38%), Morocco (12.1%), Tunisia (6%), Egypt (4.7%), Ethiopia (4.3%)	100	107,519	South Africa (47.7%), Egypt (10.5%), Morocco (8.1%), Tunisia (7.8%), Algeria (2.8%)	100	2.7%

^{*} EMRO-African countries refers to Djibouti, Egypt, Morocco, Libya, Somalia, Sudan, and Tunisia





Chaotic global scramble for Covid-19 vaccines





Access to Covid-19 vaccines: COVAX

Ensuring global equitable access to COVID-19 vaccines



Doses for at least 20% of countries' populations



Diverse and actively managed portfolio of vaccines



Vaccines delivered as soon as they are available



End the acute phase of the pandemic




Rebuild economies

With a fast-moving pandemic, no one is safe, unless everyone is safe











Supply agreements by the African Union





Supply agreements by Covax





Access to vaccines: Gavi, The Vaccine Alliance

Saving children's lives

and protecting people's health

by increasing equitable use of vaccines

in lower-income countries




















Why Gavi was launched: creating equal access to vaccines








Accelerating access, building equality



Gavi, The Vaccine Alliance, 2017




The Gavi business model: reinventing aid





Gavi's resource mobilisation model: a 3-pronged approach



Accelerating access: our vaccine portfolio


introduction/ use of stockpile 2007 2008 2009 2010 2012 2013 2014 2015 2016 2006 **INACTIVATED POLIO MULTIVALENT ORAL MENINGITIS CHOLERA** PENTAVALENT **HPV MEASLES** (CERVICAL PNEUMO->380 2ND DOSE **HEPATITIS B** COCCAL CANCER) introductio ns and campaigns **MEASLES-JAPANESE since 2000 EBOLA TYPHOID FEVER ROTAVIRUS MENINGITIS A RUBELLA ENCEPHALITIS Gavi 1.0** Gavi 2.0 Gavi 3.0 Gavi 4.0






Year of first

Affordable and sustainable vaccine prices






Immunisation coverage: closing the gap







How the Gavi model works: co-financing




How the Gavi model works: innovative finance

International
Finance Facility for
Immunisation
(IFFIm)



Advance Market
Commitment (AMC)
for pneumococcal
vaccine



Advance Purchase Commitment (APC) for Ebola vaccine



The Gavi Matching Fund











Access to Covid-19 vaccines: COVAX

Ensuring global equitable access to COVID-19 vaccines



Doses for at least 20% of countries' populations



Diverse and actively managed portfolio of vaccines



Vaccines delivered as soon as they are available



End the acute phase of the pandemic



Rebuild economies

With a fast-moving pandemic, no one is safe, unless everyone is safe







State of Vaccines: key numbers (data at 12 March 2021)

- 94 days since first countries started vaccinating¹, 75 days since all EU countries received vaccines, and
 11 days since first use of COVAX doses²
- 335 million vaccine doses have been administered:
 - 76% of these doses have been administered in 10 countries (29% in one country)
 - At least 9 different vaccines (3 platforms) have been administered³
- Campaigns have started in 144 economies:
 - o incl. 70 HICs, 40 UMICs, 28 LMICs and 6 LICs
 - 79% of HIC/UMIC economies have started vaccination campaigns, while only 43% of LMIC/LIC economies have done so
- COVAX has shipped doses to 37 countries including 31 LMIC/LICs⁴:
 - 5 LMICs & 4 LICs have started their first campaigns thanks to COVAX doses
 - In total, ~29 M COVAX doses shipped

Dec. 8, 2020 in the UK (Pfizer)


2. March 1 in Ghana and Côte d'Ivoire

^{3.} Pfizer, Moderna, Gamaleya, Sinovac, Sinopharm, SII, Bharat Biotech, AZ, Johnson & Johnson

^{4.} World Bank classification (2021). Note: The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics.

State of Vaccines: rollout has started in 144 economies

(data at 12 Mar 2021)




Status of Vx roll out per income group

^{1.} World Bank classification (2021). Note: The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics. Source: World Bank; WHO COVID-19 dashboard; Our World in data; Bloomberg; Reuters

Total doses administered per 100 population




Hosted by World Health Organization






Which economies are using which vaccine(s)?




In total, COVAX expects to deliver at least 2bn doses in 2021 of which up to ~1.8bn could go to AMC92

COVAX Facility secured volumes, Mn doses, 2021 and 2022



COVAX Facility available supply by AMC and SFP¹, Cumulative, Mn doses, 2021



WHO, 12 March 2020

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 costsharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Supply refers to volumes of vaccine available from the manufacturer. Timing of forecasts is based on anticipated release of doses from manufacturers. Volumes for expected single-dose regimen vaccine candidates doubled to ensure comparability across vaccine candidates. Volumes have been rounded to the nearest 5M.

² Non-binding agreements include memoranda of understanding and statements of intent. Following the recently announced MoU with Novavax, negotiations on final terms of the agreement and the distribution of volumes between Novavax and SII are ongoing; updates will be published in due course.

The wave of COVAX deliveries kicked off on 24 February 2021













In total, > 18 million COVAX doses have been delivered in two weeks colleges to the college of t








- More shipments to come in the coming days and weeks
- Planned shipments for the next 7 days are available on the <u>UNICEF</u> <u>Vaccine market dashboard</u> (



Countries that have received doses through COVAX



Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Public COVAX roll-out dashboard resources




1. Gavi for deliveries

https://www.gavi.org/live/covax-vaccineroll-out



3. WHO for vaccinations worldwide

https://covid19.who.int/




2. UNICEF for planned shipments and POs

https://www.unicef.org/supply/covid-19vaccine-market-dashboard



Summary of Covid-19 vaccine rollout in Africa



10 countries introduced COVID-19 vaccines before the COVAX vaccines delivery started on 24 Feb 2021

COVAX Deliveries in Countries


Vaccine Introduction in Africa





LEFT TO DIE

When HIV drugs were introduced in the mid-1990s, AIDS-related deaths kept rising in Africa but fell sharply in the United States. It took another decade for deaths to decline in Africa.







Thank you

Charles Shey Wiysonge

Twitter: @CharlesShey

Email: Charles.Wiysonge@mrc.ac.za

